Neurosurgical Robotics Market Research Report and Outlook by 2028

The global market for neurosurgical robotics is projected to expand significantly, increasing from approximately US$ 1,691.02 million in 2021 to around US$ 4,729.86 million by 2028. This growth represents a compound annual growth rate (CAGR) of 16.10% from 2022 to 2028.

This report outlines the current trends and key factors propelling the market's expansion.

The surge in the global neurosurgical robotics market can be linked to the growing number of neurosurgical procedures and the benefits offered by neurosurgical robots, which motivate leading companies to innovate and develop new products. Nonetheless, the high costs associated with the installation of these robotic systems pose a challenge to overall market growth.

Robotic technology has become integral in various surgical disciplines, with its acceptance rapidly increasing. This trend is largely driven by the demand for minimally invasive surgical options, which are known to result in fewer complications, shorter hospital stays, and enhanced aesthetic outcomes. Over the past two decades, the role of neurosurgical robots in assisting with neurosurgical operations has grown significantly. Recently, advancements have led to the development of robots capable of performing a wider array of procedures. Public interest is shaping the future of neurosurgery, placing additional pressure on neurosurgeons to incorporate robotic systems into their practices. The increasing complexity and variety of neurosurgical robots have also raised ethical questions regarding potential surgical complications and the future role of robotics in surgery.

Neurosurgical procedures involving the brain and spine demand a high level of technical skill, and robotic systems can be pivotal in achieving optimal surgical outcomes. Compared to traditional neurosurgical methods, robotic systems offer numerous advantages, such as enhanced precision, improved patient outcomes, quicker recovery times, and reduced hospital stays. Robotic neurological minimally invasive surgery (RNMIS) is becoming the preferred choice for medical facilities, surgeons, and patients alike. The integration of robotics in neurosurgery minimizes mechanical errors, shortens operation times, and maintains or improves surgical margins through minimally invasive techniques. For example, the Renaissance Guidance System, developed by Mazor Robotics, is a spine surgical robot that enhances accuracy and reduces recovery periods. It enables surgeons to plan surgeries in a three-dimensional environment and provides guidance during procedures, ensuring superior precision, especially when a patient's anatomy may shift during surgery.

Furthermore, advancements in neurosurgery are prompting key industry players to capture a larger share of the neurosurgical robotics market. Data from The Spine Market Group indicates that Johnson & Johnson holds approximately 16% of the spine market. The company's CEO has stated that they are focused on maximizing the potential and benefits of robotic and digital technologies. The increasing demand for minimally invasive surgical options is further driving the neurosurgical robotics market. In March 2019, Zimmer Biomet received FDA approval for the ROSA ONE Spine System, a robotic-assisted surgical navigation system designed to assist surgeons in performing complex thoracolumbar spine procedures. This approval also bolstered the company's existing ROSA ONE Brain Robotic system, highlighting the advantages of neurosurgical robots that encourage innovation among market players.

The global neurosurgical robotics market is categorized by component type into equipment, accessories, and services. In 2021, the accessories segment dominated the market share, while the services segment is anticipated to exhibit a higher CAGR from 2022 to 2028. By application, the market is divided into spinal and cranial categories, with the spinal segment holding a larger market share in 2021 and expected to grow at a higher CAGR during the forecast period. The market is also segmented by surgery type into open and minimally invasive categories, with the minimally invasive segment leading in market share in 2021 and projected to continue its growth. Lastly, by end users, the market is divided into hospitals, specialty centers, and others, with hospitals holding the largest market share in 2021 and expected to register the highest CAGR from 2022 to 2028.

Impact of COVID-19 Pandemic on Global Neurosurgical Robotics Market

The COVID-19 pandemic had a mixed impact on the European neurosurgical robotics market, but it has since regained momentum and is expected to continue growing. Although elective surgeries resumed in the UK and other countries by mid-2020, hospitals operated at significantly reduced capacities, leading to extended waitlists. By September 2020, around 140,000 patients in England were waiting over a year for surgeries, a stark increase from previous years. The emergence of a new, highly transmissible variant of SARS-CoV-2 led to a third national lockdown, further delaying procedures. Reports indicated a decline in elective surgeries across various specialties, including a 51% reduction in ophthalmic procedures and a 68% drop in pain management procedures. While elective surgeries in the EU increased, they remained below pre-pandemic levels. Conversely, a noticeable decrease in non-elective, emergency neurosurgical cases was observed in countries like Austria, Switzerland, and the Czech Republic, primarily due to a reduction in trauma-related conditions. Despite the challenges posed by the pandemic, emergency neurosurgical care was still delivered in these regions.

Companies in the global neurosurgical robotics market are employing various organic and inorganic strategies to enhance their market presence. Organic strategies include product launches and approvals, while inorganic strategies involve acquisitions, collaborations, and partnerships. These strategies enable companies to expand their operations and geographic reach, contributing to overall market growth. Notable developments in the neurosurgical robotics market include:

• In July 2022, Globus Medical announced the successful completion of the first spinal surgeries using ExcelsiusGPS at Westmead Private Hospital in Sydney.


• In May 2022, Renishaw revealed that its neuromate stereotactic robot, featuring neuroinspire surgical planning software, received EU Medical Device Regulation (MDR) certification from the British Standards Institution (BSI).

In preparing this report on the global neurosurgical robotics market, several primary and secondary sources were consulted, including the American Medical Association, the British Journal of Surgery, and the National Library of Medicine.